Newsroom
latest news from ose
and across our portfolio
Featured News
All News
Portfolio NewsOrbit DiscoveryOrbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeuticsPortfolio NewsScenic BiotechScenic Biotech enters cooperative research and development agreement with the National Institutes of Health for genetic modifier-based treatment approach for Niemann-Pick Type C DiseasePortfolio NewsVaccitechVaccitech appoints industry veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerPortfolio NewsGrey Wolf TherapeuticsGrey Wolf Therapeutics closes oversubscribed $49 million Series B financing to advance first-of-its-kind neoantigen creation approachesPortfolio NewsFirst Light FusionFirst Light Fusion to build demonstration facility at UKAEA’s Culham CampusPortfolio NewsAmber TherapeuticsAmber Therapeutics announces successful first-in-human implants of Amber-UI: an intelligent, closed-loop bioelectrical therapy for urge and mixed urinary incontinencePortfolio NewsScenic BiotechScenic Biotech strengthens drug discovery expertise in management team with the addition of Kristof Van EmelenPortfolio NewsOxford IonicsOxford Ionics announces £30m series A fundingPortfolio NewsPerspectumPerspectum completes $36 million first close of series C funding led by Oppenheimer HoldingPortfolio NewsArgonaut Therapeutics and Celleron Therapeutics announce completion of merger to form IngenOx TherapeuticsPortfolio NewsOrbit DiscoveryOrbit Discovery and SanegeneBio collaborate to identify targeting peptides for RNAi drugsPortfolio NewsFirst Light FusionFirst Light Fusion congratulates the National Ignition Facility on its maiden gain resultOSE NewsBehaVROxfordVR to combine with BehaVR to confront the mental health crisis with the largest VR delivery platform for evidence-based digital therapeuticsPortfolio NewsFirst Light FusionFirst Light welcomes news of possible 'Net Energy Gain' success at The National Ignition FacilityPortfolio NewsPepGenPepGen announces IND-enabling preclinical data supporting progression of PGN-EDODM1 into clinical studiesPortfolio NewsUltromicsUltromics receives FDA clearance for its breakthrough device EchoGo Heart FailurePortfolio NewsNavenioBill Kloes joins Navenio as Chief Operating Officer to drive US expansionPortfolio NewsFirst Light FusionFirst Light Fusion targets 60 MW pilot plant to accelerate tritium productionPortfolio NewsVaccitechVaccitech to host KOL webinar on the SNAPvax™ platform for inducing tolerance to treat celiac and other autoimmune diseasesPortfolio NewsOrca ComputingORCA Computing hires Per Nyberg as Chief Commercial OfficerPortfolio NewsPepGenPepGen announces positive preclinical data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, three novel duchenne muscular dystrophy candidatesPortfolio NewsVaccitechVaccitech reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsOMass TherapeuticsPublication in Nature Chemistry between Omass Therapeutics and co-founder Dame Carol Robinson demonstrates the benefits of native mass spectrometry in the interrogation of target ecosystems and drug discoveryPortfolio NewsPepGenPepGen reports third quarter 2022 financial results and recent corporate developmentsPortfolio NewsGenomicsGenomics announces successful world-first pilot using improved genomic risk assessment in cardiovascular disease prevention in the NHSPortfolio NewsOsler DiagnosticsOsler Diagnostics raises $85 million in Series C financingPortfolio NewsUtilUtil closes $6 million seed investment round led by EldridgePortfolio NewsEvolitoEvolito appoints Chris Harris as Chief Executive OfficerPortfolio NewsQuantum Motion TechnologiesQuantum Motion industry milestone brings mass production of quantum chips closerPortfolio NewsScenic BiotechScenic Biotech appoints Jens Würthner as Chief Medical OfficerOSE NewsDJS AntibodiesDJS Antibodies to be acquired by AbbViePortfolio NewsDJS AntibodiesAbbVie acquires DJS Antibodies, further strengthening immunology pipelinePortfolio NewsNucleome TherapeuticsNucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicinesPortfolio NewsPepGenPepGen presents data from its Duchenne Muscular Dystrophy program at World Muscle Society CongressOSE NewsOxford University named world's top university for the 7th consecutive yearPortfolio NewsGenomicsGenomics announces genetic risk scoring partnership with Our Future Health to test new personalised disease prevention approachesPortfolio NewsTheolyticsTheolytics presents CAF-targeting therapy for stromal rich tumours and strengthens leadership teamPortfolio NewsUltromicsUltromics joins FNIH partnership to transform heart failure detectionPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits partners with Cyxtera to improve accessibility to quantum computersPortfolio NewsPepGenPepGen reports positive data from Phase 1 trial of PGN-ED051 for the treatment of Duchenne Muscular DystrophyPortfolio NewsFirst Light FusionGovernment Chief Scientific Adviser visits UK Atomic Energy Authority and First Light FusionPortfolio NewsPepGenPepGen appoints Habib Dable to Board of DirectorsPortfolio NewsOdqaOdqa Renewable Energy Technologies emerges as frontrunner in the solar thermal industry with proprietary receiver technologyPortfolio NewsOpsydiaOpsydia secures investment to drive growth in its innovative security solutions for the diamond sectorPortfolio NewsGenomicsGenomics announces that Simon Dingemans has joined its board as the new chairPortfolio NewsRefeynRefeyn appoints Jean-Paul Mangeolle as new Non-Executive DirectorPortfolio NewsPepGenPepGen reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech reports second quarter 2022 financial results and recent corporate developmentsPortfolio NewsMiroBioGilead Sciences to acquire MiroBioOSE NewsMiroBioMiroBio to be acquired by Gilead Sciences for approximately $405 millionPortfolio NewsPepGenPepGen appoints Caroline Godfrey, Ph.D. to the company's scientific advisory boardPortfolio NewsFirst Light FusionFirst Light Fusion strikes long-term collaboration agreement with engineering leaders IDOMPortfolio NewsBrill PowerBrill powering its way to make batteries smarter with $10.5m Series A roundOSE NewsOxford Science Enterprises raises £250 millionPortfolio NewsOMass TherapeuticsOMass Therapeutics appoints Dr Jon Roffey as Vice President, Head of Medicinal ChemistryPortfolio NewsSpyBiotechSpyBiotech appoints seasoned biotech executive Mark Leuchtenberger as Chief Executive OfficerPortfolio NewsOxford IonicsOxford Ionics and Infineon join forces to develop leading trapped ion quantum processorsPortfolio NewsEvolitoEvolito acquires ElectroflightPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits raises £38 million Series A to accelerate R&D and expand into Asia-PacificPortfolio NewsPQShieldPQShield algorithms to be standardised as the National Institute of Standards and Technology (NIST) announces the first international Post-Quantum Cryptography standardsPortfolio NewsMiroBioMiroBio raises $97 million Series B financing to develop checkpoint agonists for treatment of autoimmune diseasesPortfolio NewsVaccitechVaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1Portfolio NewsPepGenPepGen reports first quarter 2022 financial results and recent corporate developmentsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Dina Anderson as Vice President of OperationsPortfolio NewsOrca ComputingOrca Computing provides UK MoD with first quantum computerPortfolio NewsBibliuEdTech leader BibliU raises $15 million in Series B fundingPortfolio NewsOrca ComputingOrca Computing completes $15 million Series A funding roundPortfolio NewsVaccitechArbutus and Vaccitech dose first patient in Phase 2a clinical trial combining therapies for the treatment of chronic hepatitis B virusPortfolio NewsTheolyticsTheolytics' £1m project with Innovate UK to develop a novel therapy for multiple myeloma patientsPortfolio NewsMoA TechnologyMoA Technology raises $44 million in Series B financing to progress novel herbicide pipelinePortfolio NewsPerspectumFDA grants clearance to Perspectum's CoverScan - A new platform-based tool to assess multiple organs in one MRI scanPortfolio NewsSalience LabsSalience Labs raises $11.5 million seed to develop ultra high-speed chips using photonics for AI applicationsPortfolio NewsPepGenPepGen announces pricing of initial public offeringPortfolio NewsSpyBiotechStudies using SpyBiotech’s vaccine technology shows potential against Covid-19 and other coronavirusesPortfolio NewsOMass TherapeuticsOMass Therapeutics raises $100 million in Series B financing to progress drug pipeline in immunology and rare diseasesPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Phil Boyd as Chief Financial OfficerOSE NewsOxford Science Enterprises appoints Richard Laxer, former Chairman and CEO of GE Capital, as a Non-Executive DirectorPortfolio NewsUtilUtil announces the closing of a seed roundPortfolio NewsRefeynRefeyn closes Series B funding roundPortfolio NewsBehaVROxfordVR technology a world-first success in automating psychological therapy using virtual realityPortfolio NewsVaccitechVaccitech announces notification of milestone and royalty revenue relating to sales of VaxzevriaPortfolio NewsOMass TherapeuticsPublication in Nature by OMass Founder, Professor Dame Carol Robinson, shows power of native mass spectrometry in drug discoveryPortfolio NewsPepGenPepGen announces first participant dosed in a Phase 1 clinical trial of PGN-EDO51 for the treatment of Duchenne Muscular DystrophyPortfolio NewsFirst Light FusionFirst Light Fusion achieves world first fusion result, proving unique new target technologyPortfolio NewsPepGenPepGen appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical DevelopmentOSE NewsNew report highlights Oxford as the UK’s leading University for spinout creation with Oxford Science Enterprises named as most active fund focused solely on a single institutionOSE NewsOxford Science Enterprises strengthens investment teams with two new appointmentsPortfolio NewsPepGenPepGen continues to build leadership team with additions of Senior Vice President, Clinical Operations and Vice President, ToxicologyPortfolio NewsScenic BiotechScenic Biotech and the Barth Syndrome Foundation announce partnership to explore genetic modifiers to find tailored treatment for complex rare diseasePortfolio NewsVaccitechVaccitech reports full-year 2021 financial results and recent corporate developmentsPortfolio NewsBibliuHigher education tech leader BibliU announces learning enablement platformPortfolio NewsMixergyMixergy partners with UK’s largest online plumbing and heating merchant to offer full range of tanks nationwidePortfolio NewsOsler DiagnosticsOsler Diagnostics publishes update on its breakthrough product, the Osler OriginPortfolio NewsOsler DiagnosticsOsler Diagnostics appoints Chris Smith as Chairman of the Board and David Berry as a Non-Executive DirectorPortfolio NewsMind FoundryMind Foundry win CogX Explainable AI Award for 2022Portfolio NewsPepGenPepGen announces approval by Health Canada of CTA to begin first in human trials of PGN-EDO51 to treat Duchenne Muscular DystrophyOSE NewsOxford Science Enterprises enters agreement with Lothbury to develop state-of-the-art R&D facilities in Oxford City CentrePortfolio NewsScenic BiotechScenic Biotech announces $31 million financing to progress pipeline of genetic modifiers in cancer and rare diseasesPortfolio NewsMiroBioMiroBio continues expansion of executive leadership team with key appointments to advance development of checkpoint agonist antibodies for autoimmune diseasePortfolio NewsOMass TherapeuticsOMass Therapeutics establishes scientific advisory board of leading expertsPortfolio NewsOrbit DiscoveryOrbit Discovery and WuXi AppTec sign agreement to access peptide discovery and optimisation technologiesPortfolio NewsOMass TherapeuticsOmass Therapeutics OdyssION™ drug discovery platform makes progress in drugging the undruggablePortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits becomes first european quantum company on Amazon BraketPortfolio NewsNucleome TherapeuticsNucleome Therapeutics appoints Nigel Clark as Chief Business OfficerPortfolio NewsUltromicsUltromics: Wolverhampton NHS cardiologists to use new cloud technology to interpret echocardiogramsPortfolio NewsFirst Light FusionFirst Light Fusion announces close of Series C fund raisePortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces formation of advisory boardOSE NewsOxford Science Enterprises strengthens investment teams with two senior appointmentsPortfolio NewsMetaboardsMetaboards announces Executive Chairman appointmentPortfolio NewsRefeynRefeyn announces the launch of its new TwoMP Auto mass photometerPortfolio NewsOpsydiaOpsydia introduces Surface ID System to complement existing sub-surface technologyPortfolio NewsQuantum Motion TechnologiesQuantum Motion opens new lab in London to build scalable quantum computerPortfolio NewsPerspectumPerspectum announces first patient recruited for multi-year collaborative primary sclerosing cholangitis (PSC) pediatric studyPortfolio NewsPQShieldPQShield raises $20 million in Series A funding to fuel global growthOSE NewsOxford Science Enterprises enters 2022 with strengthened senior leadership teamPortfolio NewsBrill PowerBrill Power announces Harwell Campus to provide testbed demonstrating energy storage innovationsPortfolio NewsOxford NanoimagingOxford Nanoimaging closes $75 million Series B led by ARCH Venture Partners and Casdin CapitalPortfolio NewsVaccitechVaccitech announces Cancer Research UK dose first patient in Phase I/IIa trial of lung cancer immunotherapy vaccinePortfolio NewsNavenioNavenio secures $12.6 million investment to accelerate global growth in healthcare and beyondOSE NewsOxford Science Enterprises Board updatePortfolio NewsUltromicsUltromics breakthrough study shows AI is a capable of independently reading stress echocardiogramsPortfolio NewsAlethiomicsAlethiomics launches to advance its multi-omics target discovery pipeline in blood cancerPortfolio NewsCircadian TherapeuticsCircadian Therapeutics announces the first subject recruited to Phase I study for CT-1500, marking move to a clinical stage companyPortfolio NewsVaccitechVaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccinesPortfolio NewsVaccitechVaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBVPortfolio NewsOxford Semantic TechnologiesDow Jones enhances product line with semantic innovation from Oxford Semantic TechnologiesPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits coming to Amazon Braket - bringing quantum to EuropePortfolio NewsMeltwater acquires AI spin-out from Oxford University’s Department of Computer Science to help build one of the largest knowledge graphs of public informationPortfolio NewsMixergyEcobubl: A new Mixergy stockist and training centrePortfolio NewsOxford FlowValve industry veteran, Colin Findley, joins Oxford Flow as Chief Strategy OfficerPortfolio NewsSpyBiotechSpyBiotech announces the appointment of Simon Jones as VP, Finance and Operations and expansion of the scientific teamPortfolio NewsVaccitechVaccitech reports third quarter 2021 financial results and recent corporate developmentsPortfolio NewsVaccitechVaccitech’s VTP-300 was well-tolerated and induced T cells against all targeted HBV antigens in both healthy volunteers and patients with chronic HBV infection in interim analysesPortfolio NewsUltromicsCaption Health and Ultromics partner to put heart disease detection and management tools in more handsPortfolio NewsCaristo DiagnosticsCaristo Diagnostics announces CT coronary perivascular fat assessment can stratify cardiac risk associated with high-risk plaquesPortfolio NewsEvox TherapeuticsEvox Therapeutics expands its exosome patent portfolioPortfolio NewsPepGenPepGen bolsters R&D team with appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical DevelopmentPortfolio NewsNavenioNavenio and HERE Technologies to bring increased efficiency to indoor location & mapping with global partnershipPortfolio NewsNucleome TherapeuticsGene linked to doubling the risk of death due to COVID-19 identified using technology exclusively licensed to Nucleome TherapeuticsPortfolio NewsOMass TherapeuticsOMass Therapeutics unveils rich drug discovery pipeline targeting intractable or inadequately drugged membrane and complex-bound proteinsPortfolio NewsVaccitechVaccitech announces publication of second Phase 1 clinical trial results of ChAdOx1 vaccine in development for the MERS coronavirusPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits collaborates with the National Quantum Computing Centre to boost UK quantum capabilityPortfolio NewsBibliuWichita State University Campus of Applied Sciences and Technology adopts BibliU Universal LearningPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits pledges carbon neutrality by 2022Portfolio NewsPepGenPepGen appoints Noel Donnelly as Chief Financial OfficerPortfolio NewsEvox TherapeuticsLandmark paper highlights Evox Therapeutics’ cutting edge exosome engineering approach for enhanced surface display of biologicsPortfolio NewsFirst Light FusionFirst Light Fusion represents UK fusion sector at the UK Government’s Global Investment SummitPortfolio NewsBrill PowerBrill Power launches the first in a new class of 'intelligent' battery management systems set to revolutionise battery performancePortfolio NewsUltromicsUltromics announces collaboration with Janssen to develop AI for patients with amyloidosis with cardiac involvementPortfolio NewsOpsydiaOpsydia technology advances to secure identity of melee diamondsPortfolio NewsPQShieldPQShield announces new hires to accelerate business growthPortfolio NewsEvolitoYASA spin-out Evolito to electrify aerospace market with ultra-high performance, low-weight electric motorsPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits appoints Peter George as Chairperson of its BoardPortfolio NewsPepGenPepGen announces new additions to leadership team and Board of DirectorsOSE NewsOxford University retains top spot in world rankings for 6th consecutive yearPortfolio NewsGenomicsGenomics academic founder and CEO, Sir Peter Donnelly, awarded Royal Society Gabor medalPortfolio NewsUltromicsUltromics raises $33 million in Series B funding to help transform cardiac disease treatmentPortfolio NewsPepGenPepGen announces closing of $112.5 million crossover financing to advance transformative therapies for neuromuscular diseasesPortfolio NewsCircadian TherapeuticsCircadian Therapeutics and Arquimea sign a collaboration agreement for the development of a molecule (AP-2) for the treatment of diseases affecting the nervous systemPortfolio NewsYASAElectric motor technology company YASA acquired by Mercedes-BenzPortfolio NewsOrbit DiscoveryOrbit Discovery announces $7.6 million funding to accelerate growth in peptide discovery businessPortfolio NewsPerspectumPerspectum launches new clinical study to investigate integrated diagnostics to enable precision medicine for liver cancer patientsPortfolio NewsTheolyticsTheolytics expands Series A financing and welcomes M Ventures as a new investorPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits delivers the UK’s first Quantum Computing as-a-ServicePortfolio NewsVaccitechArbutus Biopharma and Vaccitech announce clinical trial collaboration for chronic hepatitis B virus infectionPortfolio NewsUltromicsUltromics: EchoGo predicts cardiac-related COVID-19 mortality revealed in WASE studyPortfolio NewsFirst Light FusionUK Science Minister Amanda Solloway MP to launch First Light Fusion’s maiden ‘Big Gun’ fusion campaignPortfolio NewsBrill PowerDNV verifies Brill Power’s new battery management system technologyPortfolio NewsOxford NanoimagingOxford Nanoimaging among the +20 organisations brought together by the Cell and Gene Therapy Catapult to accelerate technology development in cell and gene therapy manufacturingPortfolio NewsPepGenPepGen strengthens leadership team with SVP of Chemistry, Manufacturing & Controls and VP of Finance AppointmentsPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces appointment of Dr Jonathan Hepple as a Non-Executive Director to its BoardPortfolio NewsNucleome TherapeuticsNucleome Therapeutics announces publication of a novel method enabling 3D genome mapping at single base pair resolution in the journal NaturePortfolio NewsOxford NanoimagingOxford Nanoimaging welcomes Dr Tyler Ralston as Chief Technology OfficerPortfolio NewsFirst Light FusionFirst Light Fusion installs UK’s biggest two-stage hyper-velocity gas gunPortfolio NewsPerspectumPerspectum partners in a new study in Singapore for the early detection of liver cancer using precision medicinePortfolio NewsVaccitechVaccitech announces closing of $110.5 million initial public offeringPortfolio NewsVaccitechVaccitech announces pricing of initial public offeringPortfolio NewsMoA TechnologyMoA Technology raises a further £5 million in Series A financing bringing the total round to £12mPortfolio NewsPerspectumPerspectum study shows measurable organ impairment in long COVID patientsPortfolio NewsUltromicsUltromics CE mark's EchoGo CorePortfolio NewsOxford EndovascularOxford Endovascular raises $10 million to develop its origami engineered medical device to prevent brain haemorrhagePortfolio NewsQuantum Motion TechnologiesQuantum Motion computing breakthrough shows blueprint for scalable futurePortfolio NewsCaristo DiagnosticsCaristo Diagnostics announces EU approval for AI technology which can predict heart attacks years in advancePortfolio NewsPerspectumPerspectum research links high liver fat to increased risk of hospitalization in COVID-19 patients with obesityPortfolio NewsVaccitechVaccitech appoints Joseph Scheeren, PharmD, to its Board of DirectorsPortfolio NewsVaccitechVaccitech doses first patient in HPV001, a Phase 1/2 clinical trial of VTP-200 immunotherapeutic for high-risk persistent HPV infectionPortfolio NewsVaccitechVaccitech completes $168 million Series B financing to advance three clinical programs through Phase 2 resultsPortfolio NewsSpyBiotechSpyBiotech announces the appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific AdvisorPortfolio NewsMoA TechnologyMoA Technology appoints Virginia Corless as Chief Executive OfficerPortfolio NewsVaccitechVaccitech appoints two independent board directorsPortfolio NewsGenomicsGenomics completes oversubscribed $30m funding roundPortfolio NewsPerspectumPerspectum lands top spot in Alantra Pharma Fast 50 rankingsPortfolio NewsPepGenPepGen announces formation of scientific advisory boardPortfolio NewsT-Cypher BioT-Cypher Bio separates from Orbit Discovery to build a pipeline of TCR therapeutics for solid tumours and other indicationsPortfolio NewsEvox TherapeuticsEvox Therapeutics completes £69.2 million Series C financingPortfolio NewsBrill Power£2.5 million for intelligent battery technology start-up, Brill PowerPortfolio NewsMixergyMixergy tanks now included at CALA Homes developmentPortfolio NewsSpyBiotechSpyBiotech raises $32.5 million in Series A funding and appoints Lutz B. Giebel as ChairmanPortfolio NewsFirst Light FusionProfessor Jerry Chittenden joins First Light Fusion’s Advisory BoardPortfolio NewsPepGenPepGen appoints James McArthur, Ph.D., as President and Chief Executive OfficerPortfolio NewsScenic BiotechScenic Biotech appoints Dr. Philippe Dro as Independent ChairmanPortfolio NewsVaccitechVaccitech doses first patient in HBV002, a Phase 1b/2a clinical trial of VTP-300 immunotherapeutic candidate for chronic HBV patientsPortfolio NewsEvox TherapeuticsJohn McHutchison joins the board of Evox TherapeuticsPortfolio NewsPerspectumPerspectum’s CoverScan MD approved by the UK’s MHRA – the world’s first integrated imaging service capable of mapping the impact of COVID-19 on the bodyPortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits lab takes delivery of first Proteox worldwidePortfolio NewsOxford Quantum CircuitsOxford Quantum Circuits state-of-the-art quantum laboratory opensPortfolio NewsOxford FlowEx-Centrica and BP boss Iain Conn joins the board of Oxford FlowPortfolio NewsUltromicsUltromics receives FDA clearance for EchoGo Pro; a first-of-kind solution to help diagnose CADPortfolio NewsTheolyticsTheolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapiesPortfolio NewsPerspectumPerspectum issued CPT Codes for LiverMultiScan by the American Medical Association to help clinicians diagnose and treat liver diseasePortfolio NewsHEXRHEXR launches smartphone fitting app: Bespoke, 3D printed helmets now accessible to millionsPortfolio NewsPepGenPepGen raises $45M in Series A funding, led by RA CapitalPortfolio NewsPrOXisenseCounterfeit drugs and illegitimate vaccines, could be a thing of the past with new breakthrough testing technology from Proxisense and Oxford UniversityPortfolio NewsRefeynRefeyn closes Series A funding round, led by Northpond VenturesOSE NewsVaccitechBreakthrough for Oxford's covid vaccine, co-invented by VaccitechPortfolio NewsEvox TherapeuticsEvox Therapeutics announces launch of strategic collaboration with the University of OxfordPortfolio NewsMind FoundryMind Foundry raises an additional $13.6 million in Series A fundingOSE NewsBase GenomicsOxford Science Enterprises announces the sale of Base Genomics to Exact SciencesPortfolio NewsVaccitechVaccitech expands management team with new hires, including CMO and CFOOSE NewsOxford Science Enterprises appoints Alexis Dormandy as Chief Executive OfficerPortfolio NewsFirst Light FusionFirst Light Fusion: Fusion energy can be the most cost competitive source of baseload power, at the same level as renewablesPortfolio NewsScenic BiotechScenic Biotech enters into genetic modifier collaboration with GenentechPortfolio NewsVaccitechVaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate